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Contribution of Metals to Respiratory
Cancer
by John M. Peters,* Duncan Thomas,t Henry Falk,* Gunter
Oberdorster,§ and Thomas J. Smith"
Thispaperreviewsstudiesontheadversehealtheffectsofexposuretometals, usingarsenicandcadmium
as examples. The carcinogenic potential of arsenic has been studied in various settings. Inhalation is
clearly related to the development of lung cancer in (copper) smelting and arsenical pesticide manufac-
turing, and also in heavily exposed wine merchants who had an additional source ofexposure by ingestion.
Animal studies have shown cadmium to be a lung carcinogen, while a study by Thun et al. provides the
best evidence to date that cadmium inhaled as CdO particles may be a human lung carcinogen. On the
basis ofthis latter study, EPA estimates the risk due to cadmium at 1.8 x 10' cases/,pg/mn, which results
in more than 100,000 excess lung cancers (lifetime). For arsenic, the risk estimate of4.29 cases/1,000 ,ug/
m3, based on epidemiologic data also results in more than 100,000 lung cancers (lifetime). This paper
reviews the bases for these estimates and presents recommendations for further research. Lung cancer
risks also exist forothermetals such as nickel, chromium, and beryllium. Further study isrequired before
a definitive conclusion can be reached about the significance and magnitude of environmental exposures
to metals as a cause oflung cancer.
This discussion of the contribution of metals, using
arsenic and cadmium as examples, will be presented as
follows: calculations ofthe excess deaths that might be
attributable to cadmium and arsenic are presented; de-
scriptions of how these numbers were derived, based
on estimates of exposure, toxicologic information, epi-
demiologic information, and risk estimation; and re-
search recommendations.
Four environments are considered: general air,
around smelters, smoking, and occupational exposures.
Exposures have been estimated on the basis of micro-
grams per cubic meter in general air and around smelt-
ers. Estimates of arsenic and cadmium from cigarette
smoking are described below. For the occupational en-
vironment, the proposed TLV was used as level of ex-
posure. The numbers of persons at risk are NIOSH's
or the authors' best estimates. Use of trade names is
for identification only and does not constitute endorse-
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ment by the Public Health Service or by the U.S. De-
partment of Health and Human Services.
EPA's upper bound unit risk estimate for cadmium
of 1.8 x 10-3 cases/,ug/m3 results in more than 100,000
lifetime excess lung cancers (1); for arsenic, the unit
risk estimate of4.29 cases/1,000 ,ug/m3 (2) also results
in more than 100,000 lung cancers over the lifetime of
those currently exposed (see Table 1 and Risk Assess-
ment section).
Pulmonary Carcinogenicity of
Inhaled Cadmium
Arecently reported increase in lungcancermortality
among cadmium production workers seems to confirm
an earlier experimental study in which a pulmonary
carcinogenic effect ofinhaled cadmiumin rats was dem-
onstrated (3,4). However, manyopenquestionsremain,
andatpresent, inhaledcadmiumcompoundscannotgen-
erally be categorized as lung carcinogens. The present
state ofknowledge on this subject is summarized in the
following overview ofexperimental animal data and ep-
idemiologic studies. This is supplemented by a brief
discussion aboutdifferencesbetweenanimaland human
studiesinordertopointoutsomefutureresearchneeds.
Water-solublecadmium saltsinjected subcutaneously
were found to cause both injection site tumors and tu-
morsofdistantorgans suchastestesandpancreas(5,6).
It appears, therefore, that cadmium is a chemical car-
cinogen that may induce tumors in different organs andPETERS ET AL.
Table 1. Estimate of number of excess lung cancer cases (lifetime) attributable to arsenic and cadmium.a
General air Around smelter Smoking Occupational
Cadmium
iLg/m 0.002-0.05 0.2-0.6 50 (TLV)
,ug/day 0.008-0.2 0.8-2.4 2.4 100
At risk 220 x 106 100,ooob 50 x 106b 100,000b
Excess cases in lifetime
EPA 1.8 x 10-3/
1 p.g/m3c 790-19,800 36-108 45,000-90,000 3,214
ArseniCd
,ug/m3 0.02-0.07 1-2 10
jig/day 0.08-0.28 4-8 0.3 20 (5 days/week)
At risk 220 x 106 500,000b 50 x 106b 1.5 x 106e
Excess cases in lifetime
Brown and Chuf 5,500-19,250 625-1,250 4,688 6,696
1.25 cases/1,000 ,ug/m3
EPA 18,876-66,066 2,145-4,290 16,088 22,982
4.29 cases/1,000 ,ium3
aAssumptions: At work, 10m3 ofair inhaled per day, 20% Cd or As retained. General, 20m3 ofair inhaled per day, 20% Cd or As retained.
Occupational exposures adjusted by 5/7 for days worked per week.
bPeters/Thomas estimates (unpublished).
CEPA data (1).
dEPA data (2).
'NIOSH estimates (unpublished).
fData of Brown and Chu (59).
by different routes of administration. This was con-
firmed by a long-term inhalation study with CdCl2 aer-
osols in rats by Takenaka et al. (4). Three groups of40
male Wistar rats were each exposed to the following
concentrations of CdCl2 aerosols (expressed as Cd):
group I, to 12.5 ,ug/m3; group II, to 25 ,ug/m3; group
III, to 50 pLg/m3. A control group of 41 animals was
exposed to filtered air. The particle size was 0.55 ,m
(mass median aerodynamic diameter). After 18 months
of continuous exposure, an additional observation pe-
riod of 13 months was added before the animals were
killed for histopathological examinations.
Primary lung tumors had developed in 15% of the
animals ofgroup I, in 53% ofgroup II animals, and in
71% ofanimals ingroup III. None ofthecontrolanimals
developed lung tumors, and most of the tumors were
adenocarcinomas ofalveolarorigin. Thisstudyprovides
sufficient evidence that cadmium inhaled as CdCl2 aer-
osols causes lungtumors inrats. In anotherstudyusing
intratracheal instillations of CdO (25 jig weekly for 3
weeks) in rats, Sanders and Mahaffey could not induce
lung tumors (7). Obviously, the method of pulmonary
administration (inhalation vs. instillation) as well as the
duration of administration are ofprime importance for
demonstrating a carcinogenic effect on the lung.
Ten epidemiologic studies have been reported since
1965 (Table 2), but effects on the lung-in particular
lung cancer-have been mentioned in only a few of
those. Lemen et al. studied cause-specific mortality in
a cohort of 292 cadmium production workers who had
been employed from 1940 through 1969 for a minimum
of 2 years (8). The exposure was mainly to CdO, but
exposure to arsenic in some areas ofthe plant could not
be excluded. An increased mortality due to cancer of
the lung and prostate was found. However, since no
attempts were made to correct for smoking habits and
for arsenic exposure, this result cannot be used as evi-
dence of a carcinogenic effect of inhaled cadmium in
humans.
Armstrong and Kazantzis reported on a very, large
cohort mortality study involving 6995 workers from 17
different plants (9). The workers were exposed to CdO
(as dust and as fume), CdS, and dust from cadmium
stabilizers. No increased lung tumor risk was found.
However, workers of the "ever high exposure group"
wereatasignificantlyincreasedrisktodieofbronchitis.
Sorahan and Waterhouse conducted a prospective
mortality study of 3026 nickel-cadmium workers (10).
The workers were grouped according to "high expo-
sure," "moderate exposure," and ";minimal exposure."
Although a significant risk oflung cancer was found in
the moderate-exposure group, the authors attributed
this to exposure of oxyacetylene in welding fumes, as
this was not observed in the high-exposure group.
In an update of the Lemen et al. study, Thun et al.
expanded the original cohort to 602 workers who had
been employed at the plant for at least 6 months be-
tween 1940 and 1969 (3). Vital status was determined
through 1978. Mortality from respiratory cancer was
significantly inereased amongtheworkers employedfor
two or more years (16 observed vs. 7 expected). A cen-
tral finding was also that lung cancer mortality in-
creased significantly with increasing cumulative expo-
sure to cadmium. The risks of developing lung cancer
due to smoking or arsenic exposure alone were calcu-
lated but did not explain the observed significant in-
crease in lung cancers.
Incontrast, Whiteetal. cametoadifferentconclusion
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Table 2. Epidemiology of cadmium carcinogenesis.
Study group Exposure Findings Reference
74 workers of CdO dust 3 cancer of prostate (61)
alkaline
battery factory
1 cancer of bronchus
(no comparison
group)
246 workers CdO dust Cancer of prostate
significantly
increased (0.6
expected, 4
observed)
536 workers of Cd(OH)2;
alkaline Ni(OH)2
battery plant
64 renal and 74
colon cancer
patients
292 cadmium
smelter
workers
Cigarette
smoking, Cd
industry
CdO (some As)
269 workers of Cd(OH)2;
cadmium- Ni(OH)2
nickel factory
and 94
cadmium-
copper alloy
workers
347 cadmium-
copper alloy
workers and
624 vicinity
workers
6,995 male
cadmium
workers of 17
different
plants
3,026 nickel-
cadmium
battery
workers
602 cadmium
production
workers
CdO (fume)
CdO, dust and
fume; CdS;
dust from Cd
stabilizers
CdO
CdO, dust and
fume; CdS,
CdSO4 (some
As)
No excess cancer
Increased risk of
renal cancer (also
exposure to other
pollutants)
Increased mortality
due to lung cancer
and prostate
cancer; no
correction for As
and smoking
Excess cancer of
nasopharynx (Ni?)
Excess deaths from
pulmonary disease
(not cancer);
elevated risk of
lung cancer in
vicinity workers
(As? smoking?)
No significant excess
lung cancers; high
risk of dying from
bronchitis in "ever
high" exposure
group
Significant increase
in respiratory
cancer in "high to
moderately"
exposed workers
but not in "high-
exposure" group
(confounding
factor?)
Lung cancer
incidence increases
significantly when
employed for 2 or
more years and
with cumulative
exposure; smoking
and arsenic
exposure do not
account for
increase
(11). Their study cohort consisted of672 cadmium pro-
duction workers at the same plant as the Thun et al.
study. These authors confirmed an increased lung can-
cer mortality among the workers, which was signifi-
cantly correlated with estimated cumulative cadmium
exposure. However, they contend that smoking and ar-
senic exposure might explain this excess oflung cancer
mortality. Adetailed analysis ofthe datato supportthis
claim is not possible because the full paper has not yet
been published.
The study by Thun et al. provides the best evidence
to date that cadmium inhaled as CdO particles may be
a human lung carcinogen (3). However, because ofthe
possibility that confounding factors may be involved,
this evidence is limited according to the criteria ofthe
International Agency for Research on Cancer (12).
Several differences have to be considered when com-
paringthe positive results ofthe rat studybyTakenaka
etal. andtheresults ofthehumanepidemiologic studies
(4). First ofall, workers were exposed to CdO as dust
or fume, which could act differently than the water-
soluble CdCl2 aerosols. The particle sizes of the dust
couldbeconsiderablylargerthanthesubmicronic CdCl2
particles administered in the rat study. Deposition in
the respiratory tract is determined by particle size,
among other things. This is indicated in differences in
tumor sites in the respiratory tract ofrats and humans:
the tumors were mostly of alveolar origin in the rats
andmostly ofbronchogenic origininthe cadmiumwork-
ers. Other factors that have to be considered are dif-
ferences in the metabolism ofinhaled cadmium (reten-
tion and accumulation), induction of metallothionein,
combined exposures of cadmium, and other pollutants
that may add to or protect from cadmium toxicity. The
importance oftherecovery period fordetoxification and
repair processes should also be considered.
Severalbasic questions remaintobe answeredbefore
cadmium compounds in general can be classified as hu-
man lung carcinogens. With regard to epidemiology, a
major point that is often overlooked is the different
physicochemical form ofa cadmium compound to which
humans are exposed. It would be desirable in epide-
miologic studies to group cohort members not only ac-
cording to duration and level of exposure but also ac-
cording to the cadmium compound to which they were
actuallyexposed. Forexample, thelarge cohortstudied
by Armstrong and Kazantzis included workers exposed
to CdO as dust and fumes, CdS particles, and dust from
Cd stabilizers, yet they were all grouped together (9).
Workers in the studies by Thun et al. (3) and White et
al. (11) had been exposed to CdO (as dust or fume),
CdSO4, or CdS. It is conceivable that cadmium in CdS
particles is less bioavailable than in CdO particles (13).
However, CdO may also exhibit different toxic effects
depending on whetherit is inhaled asfreshly generated
CdO fume or as aged CdO dust.
In addition to separating workercohorts according to
the physicochemical form ofcadmium, attempts should
also be made to quantify exposure; that is, the question
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of the dosimetry of inhaled cadmium should be ad-
dressed. This includes exposure concentrations, dura-
tion ofexposure, and particle sizes in order to estimate
the dose deposited in the deep lungorin the conducting
airways. As a supplement, biological monitoring ofcad-
mium levels in urine should be performed, as this re-
flectsbodycadmiumburden, ifkidneydamageisabsent.
Ifavailable, cadmium organ burden in autopsy material
should be determined. Combined exposures to other
metals should also be taken into account, as they may
explain additive, synergistic, or even antagonistic ef-
fects. Levels ofother air pollutants that may affect the
respiratory system (bronchitis, effect on clearance
mechanisms) should also be monitored, as they may
indirectly influence induction of lung cancer by cad-
mium. It is mandatory that epidemiologic studies on
lung cancer correct for smoking histories.
With regard to animal studies, data are needed on
the carcinogenic effect of inhaled cadmium compounds
other than CdCl2, in particular CdO (both as dust and
as fume) and CdS (both fired and unfired). These are
the relevant cadmium compounds to which workers are
exposed. The studies should be long-term inhalation
studies, and in addition to the rat, another species
should be chosen, with both sexes included. Also of
interest is a comparison of the effects of continuous
versus intermittent (8 hr/day, 5 days/week) exposures
in order to study the importance ofthe recovery phase.
Combined exposuretocadmiumpluszincaerosolswould
address the question of a possible protective effect of
zinc. Nothing is known about lung retention and trans-
location of inhaled CdS particles, which could be quite
different from inhaled CdCl2 and CdO. This should be
investigated, as it may be helpful for calculation ofthe
accumulated dose in the lung. Finally, the bioavailabil-
ity of different cadmium compounds-in particular
CdS-to the lung should be investigated in short-term
studies. These would include effects on the integrity of
bronchial and alveolar epithelium, the free cell pool of
the lung, and induction of metallothionein in different
cells of the respiratory system.
Pulmonary Carcinogenicity of
Arsenic
The carcinogenic potentialofarsenic hasbeenstudied
in a number of settings. Exposure by inhalation is
clearly related to the development of lung cancer in
(copper) smeltingand arsenicalpesticide manufacturing
(2,14) and apparently also in heavily exposed vintners
who had an additional source ofexposure by ingestion.
Exposure by ingestion (through arsenic contamination
of drnking water or by past use of medicinal arsenic
preparations) is related to the development ofnonmel-
anoma skin cancer (15) but rarely to hepatic angiosar-
coma.
Table 3 lists and briefly summarizes key information
related to the studies discussed below.
Occupational Exposures
In the United States, three smelters have been stud-
ied in detail, and several follow-up studies have been
done, at different time intervals, ofworkers at the An-
aconda, MT, and the Tacoma, WA, smelters. Studies
have also been done at smelters in Sweden and Japan.
Results ofthe studies are consistent in that a signif-
icantly increased risk for respiratory cancer has been
demonstrated among employees at all five smelters,
ranging from about 2-fold to 5-fold among all workers
studied. In the smelters studied in detail, a dose-re-
sponserelationshiptoarsenicwasfound, withthe"high-
est" exposed groups having relative risks in the range
of 5 to 10. (The relative risks for the Japanese cohort
were outside these ranges, with the relative risk of 9
for all workers and 25 for the highest exposed group.)
In these studies, mortality was analyzed for varying
lengths of time between 1938 and 1977, although ex-
posure goes back further than 1938 for many workers
included in these studies. In general, arsenic-exposure
data are sparse; limited data from periodic industrial
hygiene surveys or urine-monitoring programs were
available for ranking or estimating exposure, particu-
larly in the Anaconda and Tacoma smelters. These data
and knowledge ofsmelter operations appear to be ade-
quate for qualitative grouping of exposure levels.
Exposure data atthe Anaconda and Tacomasmelters
have also been used for quantitative risk assessment.
While sufficient data are available to carry out the as-
sessment, the limitations of the exposure data, partic-
ularly at high-exposure levels (where the range, peak,
and mean exposure levels are incompletely character-
ized), are significant.
The studies summarizedinTables3 and4have varied
comparison groups as reference populations for estab-
lishing risks (i.e., national data, state data, and local or
internal comparison data). This should be kept in mind
when relative results are being considered.
Other factors that might have influenced risk esti-
mation are smoking and the presence in smelters of
potential respiratory toxins in addition to arsenic. Data
on the interaction ofsmoking and arsenic exposure are
available in three studies and are presented in Table 4.
The results ofPershagen et al. (16) indicate a multipli-
cative effect, although those ofRencher et al. (17) sug-
gest an effect intermediate between additive and mul-
tiplicative. The data from Welch et al. are consistent
with a multiplicative effect but are based on very small
numbers (18).
In summary, the relationship ofarsenic to increased
risk oflungcancerin smelterworkers appears unequiv-
ocal. Data from two cohorts have been used by the
Environmental Protection Agency (EPA), the Occu-
pationalSafetyand HealthAdministration(OSHA), and
others for quantitative risk assessment. Data are lim-
ited in relation to smoking history, arsenic exposure,
and exposure to other potential respiratory toxins.
There are virtually no studies of pulmonary morbidity
in these groups of smelter workers.
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Table 3. Risk of lung cancer to workers at copper smelters and pesticide manufacturing plants.
Riskb
Occupation References Type of study Size Years of study' Observed vs. expected
Smelters
Anaconda, MT (18,57,67,68) Cohort
Cohort
Cohort
Cohort
Tacoma, WA (60,69-71) PMR
Cohort
Cohort
Cohort
Magna, UT
Sweden
Japan
(17)
(72,73)
(74,75)
Pesticide manufacturing plants
England
Midland, MI
(76)
(47)
PMR
Cohort
Case-control
Cohort
Case-control
Cohort
PMR
PMR
Cohort
Baltimore, MD (46) Cohort
8,047 workers
5,403 workers
1,800 workers
8,045 workers
229 deaths
527 pensioners
2,802 workers
244 deaths
29 cases
3,958 workers
19 cases
839 copper smelters
75 deaths
173 deaths
603 deaths
1,393 workers
1938-63 147 vs. 44.7
SMR = 329C
1964-77 146 vs. 88.7
SMR = 165
1938-77 Heavy exp.: 24 vs. 4.6
SMR = 527
Other exp.: 56 vs. 20.9
SMR = 267
1938-77 302 vs. 105.8
SMR = 285
1946-60 18 vs. 8.6
1950-71 40 vs. 18
1949-73 32 vs. 10.5
SMR = 304.8
1941-76 104 vs. 54.9
SMR = 189.4
1959-69 17 (7.0% vs. 2.7%)
Mort. ratio = 3.06
1960-76 Rate ratio = 4.6
1928-77 76 Observed
SMR = 288
1967-69 Relative risk = 9.0
1949-71 29 vs. 3.18
SMR = 912 (ICD 160-
3)
29 vs. 2.44
SMR = 1,189 (ICD
162)
1910-43 7 vs. 2.5
1940-72 28 Observed (16.2%
vs. 5.7%)
1940-73 20 vs. 5.8
SMR = 345
1946-77 23 vs. 8.7
SMR = 265
(U.S. white male
comparison)
23 vs. 13.7
SMR = 168
(Baltimore City white
male comparison)
aYears of study refers to observation period for development ofrespiratory cancer, not to years of exposure.
bObserved and expected numbers refer to deaths from respiratory cancer or lung cancer, whichever is used in original article.
eSMR: Standardized mortality ratio.
Table 4. Smoking and arsenic exposure in relation to lung cancer risks: data from occupational cohort studies at three smelters.
Arsenic exposure category
Arsenic (+) Arsenic (-) Very high High Medium Low Reference
SRR in lung cancer case-control studya (16)
Nonsmokers 3.0 1.0
Smokers 14.6 4.9
Percentage ofdeaths at each location due to lung cancer (17)
Nonsmokers 3.:P 0.7c
Smokers 9.2b 3.3C
Respiratory cancer SMRd (18)
Nonsmokers 620 286 89 95
Smokers 803 359 312 120
aStandardized rate ratio. bSmelter.
'Mine.
dStandardized mortality ratio.
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Cohort studies have been conducted at arsenical pes-
ticide manufacturingplants in Baltimore, MD, and Mid-
land, MI, and a proportional mortality study was done
atasheep-dipmanufacturingplantinEngland. Allthree
ofthese studies demonstrate arelationship between ar-
senic exposure and increased risk for lung cancer. The
increased risk is somewhat less (see Table 3) than that
for smelter workers, but the risks cannot be directly
compared because different arsenical compounds were
used in these settings. Characterization of arsenic ex-
posure levels in the Ott study (Midland, MI) was suf-
ficient for quantitative risk assessment, with the same
caveats as above. In the last 25 years, however, the
production of arsenical pesticides has dramatically de-
creased as their uses have been phased out.
In addition to the summary data in Table 3, several
features ofthese studies should be noted. All the data
are for males, except in the Mabuchi study, which in-
cluded a female study cohort. In most of the studies,
either arsenic exposure levels were not measured or
qualitative estimates were used. A dose-response re-
lationship between arsenic exposure (based on quali-
tative orquantitative categorization ofexposure status)
and lung cancer is consistently seen. Other chemicals
to which the study groups were exposed were usually
notmeasuredorevaluatedindetail; whenthiswasdone,
no dose-response relationship to lung cancer was seen.
Elevated mortality from causes other than lung cancer
(e.g., cardiovascular disease, cerebrovascular disease,
digestive cancer, lymphoma, and anemia) was seen in
individual studies (or in sequential studies at single lo-
cations), but no consistent patterns emerged. In the
cohort studies, reference data came from local, state,
or national data; in a few studies, two sets ofreference
datawere used. Finally, in some studies dataforcancer
oftherespiratory system wereused, butin others, only
data forlung cancer were used. In several studies, data
for both were provided, but in others, the particular
International Classification ofDiseases (ICD) Codes or
the disease categorizations werenotprovided. Allthese
differences in circumstances and methods suggest cau-
tion when quantitative results are directly compared
among the studies.
In other occupational exposures involving arsenical
pesticide applicators, an autopsy study of a group of
presumably heavily exposed vintners demonstrated a
strikingly increased proportion oflungcancer, although
the selection procedures and methods used are not fully
defined (19). Eleven of 27 had lung cancer; 4 of27 had
liver cancer. The latter may be due to simultaneous
exposure through ingestion of an arsenic-containing
drink made from grape skins. A follow-up study by
Luchtrath lends further support to this relationship; in
this update, lungcancer was found in 66% ofan autopsy
series of 163 former Moselle vintners (20).
Environmental Exposure
Analysis of U.S. county mortality data (1950-69)
demonstrated increased lung cancer rates for 31 coun-
ties containing nonferrous smelters (21). The environ-
mental exposure data and the plausibility of county-
wide exposure are not detailed. Rom et al. and Lyon
et al. found no evidence ofa relationship between lung
cancer mortality and distance between residence and
smelter (up to 20 km) for the smelter counties they
studied (22,23); again, fewenvironmentalexposure data
are provided, and it is not clear whether significant
exposure would extend beyond several kilometers from
the plant. Matanoski et al. did find an elevated lung
cancer rate in males in the census tract in which an
arsenical pesticide manufacturing facility was located
(24). Brown et al. showed 2-fold risks for lung cancer
associated with residence near a zinc smelter and in-
creased exposure to arsenic, cadmium, and several
other metals, but the authors did not consider their
results to be conclusive (25). Several additional studies
have been done with differing and not definitive results
(26-28). In summary, further evaluation and study are
required, particularly for smelter counties, before ade-
finitive conclusion can be reached about the significance
of environmental arsenic exposure as a cause of lung
cancer. In addition, the relative contributions ofair and
soil/dust arsenic levels need to be considered.
Occasional case reports of lung cancer related to
ingestion of medicinal arsenic have appeared (29). Re-
ports from Argentina mention cases of lung cancer in
relation to arsenic-contaminated drinkingwaterin Cor-
doba Province, but this relationship is not well char-
acterized. Several studies suggest an increased risk for
lungcancerinindividuals with arsenic-induced skin dis-
ease or skin cancer (30), but the data are limited.
Experimental Carcinogenesis
For many years, arsenic has been considered to be a
human carcinogen, even though there is no experimen-
tal model for carcinogenesis. Several recent studies
have suggested that intratracheal installation of ar-
senic, along with particulate matter or compounds that
increase retention in the lung (i.e., inhibit absorption),
can lead to lung tumors, particularly in the Syrian
golden hamster (31-34). It is unclear how this relates
to humans.
Issues
1. Is occupational exposure to arsenic a significant
and continuing problem? Are there industries in which
exposure exceeding the OSHA standard (10 ,ug/m3) is
likely to continue ortoappear? Is there aninternational
problem from (copper) smelters?
2. Heavyarseniccontamination ofsoil(andpotentially
of groundwater, surface water, air, etc.) exists near
abandoned copper smelters. (a) Are nearbypopulations
at significant risk of exposure? (b) Should lung cancer
risk in relation to past exposure from air or current
exposure from soil be further evaluated? (c) Should the
extent ofthe Comprehensive Environmental Response
Compensation and Liability Act of1980 (Superfund) re-
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medialaction (i.e., environmentalcleanup)atthesesites
be dependent on the results of such studies?
3. At the current occupational standard, are workers
still at significant risk? If risk assessment calculations
suggest that this is so, should the standard and/or the
risk assessment approach be reconsidered?
4. Howrelevant arerecentexperimentalcarcinogeni-
city data to human arsenic carcinogenesis? How rel-
evant are they to other particulate respiratory carcin-
ogens?
5r Is auniquehistologictype oflungcancerassociated
with arsenic exposure? Results of the two studies al-
ready done show different histological distributions
from those expected, but they disagree on which his-
tological type is increased (35,36).
Exposure Assessment for Arsenic
and Cadmium
Thegoalofenvironmental health is to control orelim-
inate risks of lung cancer from environmental expo-
sures. When exposure cannotbe eliminated, control can
best be achieved ifthe quantitative relationship (dose-
response curve) for exposure and risk is known.
The general relationship between exposure and can-
ceris diagrammed in Figure 1 (37). Exposure is defined
as the composition and concentration ofthe agent in the
breathing zone; dose is defined as a time function ofthe
concentration of the causal agent at the site of action,
such as metal ions in the pulmonary tissues. Dose is
quantitatively related to the intensity of the cellular
effect, whereas measures ofexternal exposure may not
be. The cancer risk is related to the intensity and du-
ration of the cellular effects and additional biological
factorsassociated withthenaturalhistoryofthedisease
(e.g., the lag or induction time) and with host factors
(e.g., age, sex, and race), quantitative effects ofwhich
are included in the weighting function, g(T-t). Several
key factors are indicated in this diagram. (1) Agent
characteristics affect both the dose and the effect: in
vivo solubilization ofmetal compound, ability ofthe ac-
tive form (e.g., metal ion) to enter target cells, and
ability ofthe active form to cause damage orcontribute
to the cancer-development process. (2) Exposure con-
ditions control the amount deposited in various parts of
therespiratorytract: airconcentration, watersolubility
ofgases (e.g., arsine), and size distribution ofparticles.
(3) Personal factors, includingpulmonary geometry and
pharmacokinetics, control the dose by controlling the
tissue concentration: fraction ofparticles deposited and
ratesofabsorption, transport, storage, metabolism, and
excretion; personal factors such as age, age at first ex-
posure, sex, and race are alsoimportant forcancerrisk.
(4) Time factors control the dose and development of
the effect: duration of exposure at various levels and
the occurrence ofsufficient lagtime. (5) The mechanism
of the cellular effects and the natural history of the
cancer are summarized. All these factors work in con-
cert to produce a cancer risk. The chemical form ofthe
metal and its route ofentry are especially important.
The chemical form ofthe metal is important because
it controls the bioavailability, the time course oftissue
concentration, and the ability to cause damage or con-
tribute to the cancer process. Figure 2 shows how acid
solubility may affect tissue concentration of cadmium
ions Cd"2 produced by the same size particles ofthree
different compounds with different rates of solubiliza-
ocesses
Exposure Pulmonary Tissue Effects
O p Airborne Deposit I (Cd tissue
o par~~~~Etice
- particles i(Cd+2, As+3)
E(t) I I Cellular
TIME particles ... ions effects
I effects Cancer T particles - ~ . ]---- ions ---m'- effects R(t)
Tissue Dose, D(t)
FIGURE 1. Model of environmental lung cancer for metal exposures. The exposure-dose relationship is
D(r) = E(t)f(I,F,T -t) dt
whereE(t) is thebreathing zone concentration overtimeandf(I,F,T-t) is afunctionthatdepends onthe inhalationrateI, thefractiondeposited
at the target site F, and other pharmacokinetic factors controlling the ion concentration within the target cells. The dose-cellular effect
relationship is
C(T) = 1 + 13D(T)
where X is an effect factor characteristic of the specific chemical compound. The cellular effect-cancer risk relationship is
R(T) C(T)g(T,) dr
where Tis the total time exposed andg(T,) is a weighting function that reflects the latency and host factors such as age, age at first exposure,
sex, and race.
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Ingestion
Tissue CdCI2
Concentration
Cd+' / \
Time
FIGURE 2. Hypothetical tissue concentrations offree ion (excluding
protein-bound) produced bycadmium compoundswithvariousacid
solubilities (CdCl2 > CdO > CdS) after a single exposure.
tion and total solubility. All produce the same total
amounts ofCd"2 in the tissues (assuming no clearance
ofthe particles), but the time course and peak concen-
tration are different. Thus, even though all the com-
pounds produce the same active agent, the risks of ef-
fects may be different. Particle-size distribution is
similarly very important, because it affects where the
particles are deposited intherespiratorytractandtheir
solubilization rates. In addition to controlling the tissue
dose, chemical form controls the ability ofthe agent to
cause effects. For example, arsenic trioxide in smelter
dust has a different toxicity than arsenic in cacodylic
acid used as a herbicide.
Route ofentry is also important for lung cancer risk.
This may be seen in Figure 3, which shows a simple
four-compartment model ofthe body. Metal compounds
entering by inhalation may be deposited on the target
tissues, whereas those entering by the gastrointestinal
(GI) route must passthrough theliver, wheretheymay
be partially metabolized: arsenic methylated, or cad-
mium bound to metallothionein, and then diluted with
blood returning to the lungs from the other organs. As
a result, the pulmonary tissues generally will not ex-
perience the same dose with GI exposure as with in-
halation unless the amount ingested is massive. This is
consistent with the lack of increased lung cancer for
either arsenic or cadmium exposures by the GI route.
Patients ingesting Fowler's solution, which contains
large amounts of arsenic trioxide, have been reported
to be at risk of lung cancer, but populations ingesting
arsenic-contaminated drinking water are not (38).
Arsenic and cadmium are both found extensively
throughout the environment as a result ofboth natural
and human activities, and there is a natural cycle of
these compounds through the environment (39-42).
However, aside from arsenic trioxide from volcanic ac-
tivity, only humanactivities produce significant air con-
centrations. Hotmetallurgical processes, especially pri-
mary and secondary nonferrous smelters (copper, lead,
zinc, and their alloys), are the main sources of high
occupationalandlocalcommunityexposurestocadmium
FIGURE 3. Four-compartment model of the body for evaluation of
lung tissue dose by inhalation and ingestion routes of exposure.
oxide and arsenic trioxide (43-45). Although large total
amounts of arsenic and cadmium may be released by
coal combustion and municipal incinerators, the aircon-
centrations produced are low because the metal content
of the materials burned is low (41). There are many
other processes that may be limited local sources of
occupationalexposurestoinorganic arsenic: combustion
of wood-containing preservatives or wastes containing
arsenic compounds, glass and enamel making, and pro-
duction ofhigh-purity arsenic metal, semiconductor al-
loys, lead shot, and some lead and copper alloys (3). In
the past, various arsenic oxides have been used in pes-
ticides and have been associated with major inhalation
exposures (46,47). Significant occupational exposures
are produced in the use of cacodylic (dimethylarsinic)
acidas adessicantforcottonandinforestryapplications
(48). The production oforganic arsenic compounds may
also lead to local community and occupational expo-
sures, but the levels of exposure have not been docu-
mented. Examples ofthese processes are textile print-
ing; tanning; and production and use of antifouling
paints, lubricants, and arsenic-based pesticides, herbi-
cides and wood preservatives (43). Trivalent arsenic
(As+ ) is oxidized to pentavalent arsenic in the outdoor
environment, so smelter emissions deposited in the soil
aroundthe plantare converted tolesstoxicpentavalent
arsenic. However, some arsenate is reduced in vivo to
arsenite, asthe environmental oxidationisnotfullypro-
tective (49,50). Thus, soil contamination around indus-
trial sources may be a source of inhalation exposures,
as hasbeennoted forsoilaround smelters contaminated
with lead (51). Production of nickel-cadmium batteries
is also an important source of occupational inhalation
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exposure to cadmium oxide (52). Limited amounts of
cadmium are used as the metal and sulfate for plating
and alloys, as the oxide and sulfide for pigments, and
as various compounds for additives to plastics and rub-
ber. It is also present as an impurity in zinc products,
phosphate fertilizer, and waste products from many op-
erations producing nonferrous metals. Cadmiumin par-
ticulate urban air pollution is probably predominantly
oxide from hot-metal operations and combustion of
products containing trace amounts of cadmium; how-
ever, it may also be other compounds if there are in-
dustrial operations that produce or use cadmium.
The levels of exposure to arsenic and approximate
daily pulmonary input by inhalation have been sum-
marizedinTable 5fromseveralsources. Thepulmonary
inputs for occupational and general exposures were es-
timated for particles with a mass median diameter of2
,um by either assuming that 10 m3 are inhaled by a
worker per 8-hr day and 20% of the inhaled dust is
deposited inthe respiratory tract, orthat, for ageneral
community exposure, 20 m3 are inhaled per 24-hr day
and 20% is retained. (These figures do not indicate
where in the respiratory tract the particles are depos-
ited, and they are sensitive to the particle-size distri-
bution, the average rate and depth of inspiration, and
the fraction oftime the subject is exposed, which may
be affected dramatically by indoor/outdoor differences
Table 5. Sources of arsenic and cadmium inhalation exposure.
Arsenic Cadmium
(25-40% deposition (25-90% deposition
and absorption and absorption
depending on depending on
particle size and compound and particle
chemical form) size distribution)
Occupational exposure (8-hr exposures)
Past cancer studies
Pesticides 0.1-50 mg/m3 (Pb, Ca,
Mg arsenate, Cu
acetoarsenite)
200-20,000 ,ug As/day
Smelters 0.3-11 mg/m3 (As203, 0.04-17 mg/m3 (Cd
As sulfide) oxide, sulfate,
600-22,000 j.g/day sulfide)
80-34,000 ,ug/day
Current exposure limits
OSHA < 10 ,ug/m3 (inorg. As) < 100 jig/m3 (CdO
fume)
< 20 ,ug/day < 200 ,.g/day
TLV None, inorganic As < 50 ,ug/m3 (CdO
cancer agent fume)
< 100 jg/day
Cigarettes
Occupational < 20 ,ug/cigarette
contamination < 40 ,ug/day
General < 0.15 jig/cigarette 1-2 jig/cigarette
contamination < 0.3 ,ug/day 2-4 jig/day
Air pollution (24-hr exposure)
Near source 1-2 ,ug/m3 near smelter 0.2-0.6 ,ug/m3
4-8, g/day 0.8-2.4 ,g/day
General 0.02-0.07 tig/m3 0.002-0.05 jug/m3
0.08-0.28 jg/day 0.008-0.2 ,ug/day
for air pollution exposures.) The past respiratory ex-
posures associated with most occupational settings,
such as copper smelting or herbicide applicators, are
dramaticallyhigherthananyoftheotherenvironmental
exposures, where the range ofoccupational pulmonary
intakes is 200 to 20,000 ,ug/day of arsenic trioxide or
pentoxide. Clearly, the composition will vary with the
specificchemicalcompoundbeingusedorproduced. Un-
der the current permissible 8-hr OSHA occupational
exposure of 10 ,ug/m3 of inorganic arsenic, the arsenic
intake by inhalation should be less than 20 ,ug/day, al-
though the actual distribution of exposures is not
known. This may be contrasted to the exposures ofres-
idents living near a copper smelter, who may inhale 1
to 2 Rg/m3 of arsenic trioxide during a 24-hr exposure
and have a pulmonary intake of 4 to 8 ,ug/day if their
indoor exposure is the same as outdoors (which it prob-
ably is not). There are other localized exposures to in-
dustrial sources of arsenic compounds and to airborne
dusts contaminated with pesticides or herbicides. Ur-
ban residents would have an approximate range ofpul-
monary doses of 0.08 to 0.28 R,g/day. Cigarettes may
be the major source of inhalation exposure to arsenic
(probably trioxide), <3 ,ug/day, if exposure is not oc-
cupational, but this is uncertain because of insufficient
data.
Ithasbeenpossibletodeterminetotalarseniccontent
ofenvironmentalandtissuesamplesforthelast30years
(43). Only recently has it become possible easily to de-
termine arsenite and arsenate and the two common
methylated forms (monomethylarsenic and dimethylar-
senic acids, and their salts) (53). Because the toxic and
probably carcinogenic properties of arsenic are deter-
minedbyitschemicalform, application ofthesemethods
is very important. Dimethylarsinic acid in the urine is
the best biological index of exposure to inorganic or
methylated forms of arsenic (54). The lack of specific
chemical information on arsenic forms has made it dif-
ficult to interpret the risk represented by some envi-
ronmental data on total arsenic exposures.
A summary of the levels of cadmium exposure and
approximate daily doses by inhalation intake are given
in Table 5. As with arsenic, past and current occupa-
tional exposures are the highest source of respiratory
intakeandareprobablyordersofmagnitudehigherthan
any other source of airborne exposure. Cigarettes are
a major source of respiratory intake in the absence of
occupational exposure, which may equal or exceed the
intake from air pollution from point sources.
Accurate analysis oftotal cadmium in environmental
samples has been possible since the early 1970s (55).
However, because of the analytical difficulty, no at-
tempt has been made to determine the chemical form
ofthe cadmium, which makes it difficult to estimate the
bioavailability of cadmium in these materials. This has
occurred in spite of Friberg and co-workers' recom-
mendationin 1974thatthecomposition ofcadmiumcom-
pounds in air pollutants should be determined. Internal
doses can be estimated with biological monitoring data
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obtained from analysis ofurine or blood samples or by
in vivo measurement ofliver and kidney burdens (56).
Risk Assessment
Arsenic
The epidemiological data onthe carcinogenicity ofar-
senic has been reviewed by the EPA (2) and used for
purposes ofquantitative risk assessment. The analysis
wasconfinedtodatafromthreereportsontheAnaconda
smelter workers (57-59), the American Smelting and
Refining Cdmpany (ASARCO) smelter workers (60),
and the Dow pesticide manufacture workers (47). The
latter was deemed the least reliable for quantitative
estimates, in part because it also included exposures to
pentavalent arsenic whereas the others involved only
trivalent arsenic, and it was excluded from their final
risk assessment. Each ofthese data sets (with the ex-
ception of the Brown and Chu analysis based on mul-
tistage models described below) was fitted by Poisson
regression techniques to four models: relative risk or
absolute risk, as both linear and quadratic functions of
cumulative exposure. In all data sets, linear models fit
better than quadratic models, and absolute risk models
fitbetterthanrelativeriskmodels. Thus, onlythelinear
absolute risk model fits were retained for the purpose
ofrisk assessment. Forthe ASARCO smelterworkers,
two versions ofthe datawere available, one with no lag
inthe exposure and onewith a 10-yearlag; nolags were
used in either the Lee-Feldstein or the Higgins et al.
data. The resulting slope coefficients were then applied
to a standard life table calculation to derive a "unit risk"
estimate, being the excess lifetime risk of lung cancer
resulting from a constant exposure to 1 ,ug/m3. The es-
timates obtained in this way ranged from 2.8 to 4.9
excesscancersper 1,000person-,ug/m3 fortheAnaconda
smelter and from 6.8 to 7.6 for the ASARCO smelter.
With the exception ofthe 10-year lag involved in one
ofthe ASARCO estimates, none ofthese risk estimates
take any account oflatency. The 10-year lag allows for
aperiod ofnoeffectimmediatelyfollowingexposurebut
assumes thatthe effectremains constantthereafter. An
alternative is posed by the use ofmultistage models in
the analysis ofthe Anaconda smelterbyBrownand Chu
(59). This involves a weighting of each increment of
exposure by a power function of both age at exposure
and time since exposure, the exponents of each de-
pending on the stage ofthe carcinogenic process that is
influenced by arsenic exposure. Brown and Chu con-
trasted a first and penultimate stage effect and found
the latter to give a much better fit to the data. Inte-
gration ofthis weightingfunction overages at exposure
then allowed the slope coefficient they derived to be
expressed in a similar manner as a unit risk, resulting
in an estimate of 1.25 per 1,000 person-pRg/m3, much
smaller than the other two estimates from this smelter.
Thedifferenceiseasilyexplainedbythefactthat, under
the assumption ofa late-stage effect, the increased risk
occurs rapidly after exposure and then tapers off after
cessation ofexposure. Thus, a high slope coefficient es-
timated from truncated followup ofan occupational co-
horttranslates intoamuchlowerlifetimeriskestimate.
Thefinalunitriskestimate suggested by EPA of4.29
per 1,000 person-,g/m3 was obtained by taking a geo-
metric mean ofthe five risk estimates (2).
Cadmium
The EPA risk assessment for cadmium is based on
the data of Thun et al. (3). Restricting the cohort to
those first employed after 1925 with at least 2 years of
employment, 16 lung cancers were observed, with 7.0
expected. Using a mean cumulative exposure estimate
of 1741 ,ug-day/m3 and methods similar to those de-
scribed above, a unit risk estimate of 1.8 x 10-3 per
person-pug/m3 was derived (1).
The EPA risk assessment document for arsenic (2)
includes a comparative table of "relative carcinogenic
potencies" among 52 chemicals evaluated by the carcin-
ogen assessment group as suspect human carcinogens,
based largely on toxicologic evidence. The potency in-
dex given for arsenic is 2000; for cadmium it is 700.
Research Recommendations
Using currently available data on levels ofinhalation
exposure to arsenic in the most likely settings for ex-
posure (ambient air, small communities around smelt-
ers, occupationalexposure, and cigarette smoking), and
applyingthe respective total population at risk for each
type ofexposure, estimates ofnational exposure to ar-
senic and cadmium in the United States were derived.
The application ofthe standard risk assessment models
for extrapolating arsenic and cadmium dose-response
datatonational exposure estimatesledtotheprediction
of more than 100,000 excess cases of lung cancer (life-
time) due to both arsenic and cadmium exposure in the
U.S. population (see Table 1). Additionally, lungcancer
risks exist for other metals such as nickel, chromium,
and beryllium.
Ifthese estimates are correct, significantly increased
prevention activities are called for. Ifthe estimates are
incorrect or ifthere are large areas ofuncertainty that
can be resolved, it is important to identify such prob-
lems so that scarce resources can be better used else-
where. Thefollowingrecommendations have beeniden-
tified to resolve this issue. Analogous recommendations
could be developed for other metals that are or may be
lung carcinogens.
Exposure Assessment
Recommendation 1: A national effort should be
mounted to estimate the populations exposed to specific
metal compounds by level ofexposure so that priorities
and the magnitude of the problem from carcinogenic
metals can be determined.
Risk assessment requires knowledge of the number
of people exposed to various levels of specific metal
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compounds for which dose-response relationships are
known. At present, these data do not exist for either
occupational groups or local community groups near
point sources. NIOSH's National Occupational Hazard
Survey attempted to provide some of this information
but was limited and did not include determinations of
exposure levels. Data on communities around point
sources may exist but have not been collected and prob-
ably are very uneven.
To acquire needed information, improved dose-re-
sponse data and risk assessment models are needed.
Specifically, the following are recommended.
Recommendation 2: Followup of existing cohorts
should continue in order to refine knowledge about the
evolution ofrisk over time.
Recommendation 3: The environmental data base
for these cohorts should be further refined by recon-
struction of physical and chemical attributes and bio-
logical monitoring approaches.
Recommendation 4: To support the above recom-
mended reconstruction, occupational environments in
foreign countries that resemble the conditions to which
the U.S. cohorts had been exposed should be identified
and the necessary environmental measurements be
made.
Recommendation 5: Cohorts of foreign workers
with these same occupational exposures should be iden-
tified, and their cancer experience should be assessed,
both retrospectively and prospectively.
Recommendation 6: There should be studies of all
sufficiently large populations exposed by virtue ofres-
idence in the vicinity of all active or formerly active
smelters to arsenic or other metals that can be carcin-
ogenic. They should be studied in terms of cancer in-
cidence or mortality, by cross-sectional, case-control,
cohort, or other unspecified approaches, in relation to
a thorough environmental assessment.
Recommendation 7: Data from the existing cohort
studies, refined asdetailedabove, shouldbemade avail-
able to an appropriate, multidisciplinary team ofinves-
tigators foranalysis ofrelevant issues. Theteam should
have access to raw data from all studies of the same
agent.
Animal Studies
Recommendation 8: Long-term inhalation studies
with cadmium oxide, as dust and as freshly generated
fumes, aswell as cadmium sulfide particles, are needed.
These studies should be performed in the rat and at
least one other species and should include both sexes.
Such studies would allow comparison of the relative
carcinogenic potencies of the different cadmium com-
pounds. For example, the question can be answered as
to whether cadmium sulfide, an important occupation-
ally encountered substance, has a higher or lower car-
cinogenic potency than cadmium oxide.
Recommendation 9: A suitable animal model for
studyingarsenic andlungcancerneedstobedeveloped.
Recommendation 10: Combined exposures of ani-
mals to cadmium and zinc, in both short- and long-term
experiments, should be performed to address the ques-
tion of the possible protective effect of zinc. Zinc is
significant in many occupational exposures to cadmium.
Likewise, the effects of arsenic and cadmium, in com-
bination with otherenvironmentally relevant pollutants
such as cigarette smoke and sulfur dioxide, should be
investigated.
Recommendation 11: Animal studies should in-
clude animals of varying ages and durations of expo-
sures. The question of a possibly greater effect on the
growing lung should be investigated by starting expo-
sure at a very young age. The importance ofthe recov-
ery phase should be studied by comparing intermittent
versus continuous exposure.
Recommendation12: Studies are needed onthere-
tention of cadmium and arsenic of different chemical
forms to obtain more background data for modeling.
Recommendation 13: The acute pulmonary effects
ofthe metals should be studied in more detail. For ex-
ample, study is needed on effects on the bronchial and
alveolar epithelium (using different particle sizes), ef-
fects on alveolar free cells and on biochemical markers,
and induction of metallothionein by different cadmium
compounds. The effects on the immune system after
inhalation exposure should also be investigated.
Recommendation 14: Information on mechanisms
from animal studies should be supplemented by invitro
studies. Invitro studies should include cellculture stud-
ies on the uptake of the metals into the cells of the
respiratorytract. Themetabolism ofthemetalsinthose
cells should also be studied, for example, methylation
ofarsenic or the involvement ofmetallothionein in cad-
miummetabolism. Finally, studies shouldbe perforned
of metal-DNA interactions, metal uptake into the cell
nucleus, and binding ofthe metal to RNA or DNA.
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